PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment

Leukemia. 2017 Jul;31(7):1645-1647. doi: 10.1038/leu.2017.110. Epub 2017 Apr 3.

Authors

D Jones¹, J A Woyach², W Zhao¹, S Caruthers³, H Tu³, J Coleman¹, J C Byrd², A J Johnson², G Lozanski¹

Affiliations

¹ Department of Pathology, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
² Division of Hematology, Department of Internal Medicine, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.
³ James Polaris Molecular Laboratory, The Ohio State University and James Cancer Hospital, Columbus, OH, USA.

PMID: 28366935
DOI: 10.1038/leu.2017.110

No abstract available

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase
C2 Domains / genetics*
Drug Resistance, Neoplasm / genetics*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Mutation*
Phospholipase C gamma / genetics*
Piperidines
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / genetics*
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*

Substances

Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Protein-Tyrosine Kinases
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human
Phospholipase C gamma
Adenine